United States Semen Analysis Market Forecast 2025-2032

The United States semen analysis market is predicted to progress with a CAGR of 6.16% over the forecast period 2025-2032. The market was valued at $310.45 million in 2024 and is expected to reach a revenue of $502.56 million by 2032.

The growth of the semen analysis market in the United States is attributed to increasing incidences of male infertility, advancements in diagnostic technologies, the expansion of fertility clinics and ART centers, and growing awareness of reproductive health.

The rising preference for convenient and private home semen test kits also contributes to market expansion. However, the United States semen analysis testing market is likely to be hindered by the high costs of advanced diagnostic procedures and sociocultural stigmas associated with male infertility and fertility testing.

MARKET INSIGHTS

The market’s growth is propelled by technological advancements, such as the integration of artificial intelligence (AI) and machine learning (ML) in diagnostic tools, enabling greater accuracy and efficiency. According to a recent analysis, AI-driven semen analyzers have demonstrated the ability to enhance the precision of sperm count tests, motility, and morphology assessments, making them a vital tool in both clinical and home settings.

Additionally, the expansion of fertility clinics and ART centers, and growing awareness of fertility testing and reproductive health across the United States ensures broader access to reliable diagnostic solutions. This progress is also contributing to the future demand in the semen analysis market, which is expected to grow with increased focus on laboratory testing of semen and improvements in the semen analysis procedure.

Semen analysis technologies are projected to witness continued growth, with computer-assisted semen analysis (CASA) systems playing a pivotal role. CASA systems combine advanced imaging and computational semen analysis tools to provide accurate and standardized results, reducing variability in manual assessments.

Their adoption is expected to increase significantly, especially in fertility clinics and diagnostic laboratories. Moreover, the rising demand for sperm count home testing kit options reflects a shift towards comfort and convenience-centered patient care, driven by accessibility and the need for privacy.

This shift also aligns with the growing popularity of male fertility test options, which provide individuals with a convenient method for assessing their reproductive health. Furthermore, advancements in semen quality assessment are driving improvements in diagnostic accuracy, while the increasing use of male fertility supplements is contributing to overall market growth.

SEGMENTATION ANALYSIS

The United States semen analysis market is segmented into diagnostic technique, testing kits and reagents, age group, and end-user. The diagnostic technique category is further classified into microscopic examination, computer-assisted semen analysis (CASA), and other diagnostic techniques.

Microscopic examination remains a widely used technique for semen analysis, particularly in clinical settings, due to its cost-effectiveness and ability to meet basic diagnostic needs. This traditional technique enables the direct observation of sperm count, motility, and morphology, providing healthcare professionals with valuable insights into male reproductive health.

Despite the emergence of advanced technologies, microscopic examination continues to be favored due to its accessibility, simplicity, and ability to deliver accurate results with minimal equipment. Ongoing advancements in microscopy, such as improved imaging clarity and enhanced staining techniques, are further refining the precision and ease of this method, ensuring its continued relevance in the market.

COMPETITIVE INSIGHTS

Major companies operating in the United States semen analysis market include bioMérieux SA, Cooper Companies, Inc, DNA Diagnostics Center, Hamilton Thorne Inc, etc.

Hamilton Thorne Inc specializes in the design, manufacture, and marketing of precision instruments, consumables, software, and services for Assisted Reproductive Technologies (ART), research, and cell biology markets.

The company’s product portfolio includes precision laser systems, Computer Assisted Sperm Analysis (CASA) systems, imaging systems, and related consumables, serving fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, and biotechnology firms. Operating globally, Hamilton Thorne has facilities and a network of distributors across North America, Europe, and other regions.